Bavarian Nordic Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
1,861
- Stock Symbol
-
BAVA
- Investments
-
4
- Share Price
-
$36.43
- (As of Thursday Closing)
Bavarian Nordic General Information
Description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
Contact Information
Website
www.bavarian-nordic.comCorporate Office
- Philip Heymans Alle 3
- 2900 Hellerup
- Denmark
Corporate Office
- Philip Heymans Alle 3
- 2900 Hellerup
- Denmark
Bavarian Nordic Stock Performance
As of 19-Nov-2026, Bavarian Nordic’s stock price is $36.43. Its current market cap is $2.72B with 74.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $36.43 | $35.74 | $26.27 - $38.42 | $2.72B | 74.6M | 216K | $3.86 |
Bavarian Nordic Financials Summary
As of 30-Sep-2026, Bavarian Nordic has a trailing 12-month revenue of $987M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,185,000 | 1,905,585 | 1,834,288 | 1,845,472 |
| Revenue | 987,023 | 943,371 | 829,165 | 1,024,870 |
| EBITDA | 309,248 | 376,147 | 235,834 | 305,047 |
| Net Income | 139,425 | 207,800 | 143,311 | 214,076 |
| Total Assets | 2,284,228 | 2,351,749 | 2,009,859 | 2,131,049 |
| Total Debt | 18,642 | 20,581 | 17,893 | 21,573 |
Bavarian Nordic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bavarian Nordic Comparisons
Industry
Financing
Details
Bavarian Nordic Competitors (31)
One of Bavarian Nordic’s 31 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| OncBioMune Pharmaceuticals | Corporate Backed or Acquired | Baton Rouge, LA |
Bavarian Nordic Signals
Bavarian Nordic Investments & Acquisitions (4)
Bavarian Nordic’s most recent deal was a Merger/Acquisition with Emergent BioSolutions (Travel Vaccines) for . The deal was made on 15-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Emergent BioSolutions (Travel Vaccines) | 15-Feb-2023 | Merger/Acquisition | Drug Discovery | ||
| GlaxoSmithKline (two travel vaccines) | 31-Dec-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Applied Process Company | 27-Sep-2018 | Corporate | Other Pharmaceuticals and Biotechnology | ||
| BN ImmunoTherapeutics | 11-Nov-2009 | Corporate | Drug Discovery |
Bavarian Nordic ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
20.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Bavarian Nordic Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Bavarian Nordic Sweden | Helsingborg, Sweden | 2021 | |
| Aktieselskabet Af 1. Juni 2011 I | Hellerup, Denmark | 2011 |
Bavarian Nordic FAQs
-
When was Bavarian Nordic founded?
Bavarian Nordic was founded in 1992.
-
Where is Bavarian Nordic headquartered?
Bavarian Nordic is headquartered in Hellerup, Denmark.
-
What is the size of Bavarian Nordic?
Bavarian Nordic has 1,861 total employees.
-
What industry is Bavarian Nordic in?
Bavarian Nordic’s primary industry is Drug Discovery.
-
Is Bavarian Nordic a private or public company?
Bavarian Nordic is a Public company.
-
What is Bavarian Nordic’s stock symbol?
The ticker symbol for Bavarian Nordic is BAVA.
-
What is the current stock price of Bavarian Nordic?
As of 19-Nov-2026 the stock price of Bavarian Nordic is $36.43.
-
What is the current market cap of Bavarian Nordic?
The current market capitalization of Bavarian Nordic is $2.72B.
-
What is Bavarian Nordic’s current revenue?
The trailing twelve month revenue for Bavarian Nordic is $987M.
-
Who are Bavarian Nordic’s competitors?
Novartis, Cipla, Takeda Pharmaceutical, Astellas Pharma, and OncBioMune Pharmaceuticals are some of the 31 competitors of Bavarian Nordic.
-
What is Bavarian Nordic’s annual earnings per share (EPS)?
Bavarian Nordic’s EPS for 12 months was $3.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process